GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: JAZZ
Buy $200

JAZZ PHARMA INC (NASDAQ: JAZZ) upgraded to Buy with price target $200 by R. F. Lafferty

Wednesday,  Nov 5, 2014  12:25 PM ET by Kristen Bailey

R. F. Lafferty upgraded JAZZ PHARMA INC (NASDAQ: JAZZ) to Buy with price target $200 with today's
price of $170.39. R. F. Lafferty rated JAZZ PHARMA INC (NASDAQ: JAZZ) to Neutral with price target $140 on 01/14/2014, when the price was $143.28. JAZZ PHARMA INC's stock price gained 19% since then.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens, JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder, and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.

R. F. Lafferty



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy